Premium
Selective dopamine DA 1 stimulation with fenoldopam in cirrhotic patients with ascites: A systemic, splanchnic and renal hemodynamic study
Author(s) -
Hadengue Antoine,
Moreau Richard,
Bacq Yannick,
Gaudin Christophe,
Braillon Alain,
Lebrec Didier
Publication year - 1991
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840130116
Subject(s) - fenoldopam , medicine , renal blood flow , ascites , plasma renin activity , endocrinology , splanchnic , portal venous pressure , hemodynamics , portal hypertension , cirrhosis , dopamine agonist , blood pressure , dopamine , renin–angiotensin system , dopamine receptor , dopaminergic
We studied the effects of fenoldopam, a selective dopamine DA 1 agonist on systemic and splanchnic hemodynamics, renal blood flow and sodium excretion in 12 patients with alcoholic cirrhosis and ascites. Hepatic, azygos and renal veins were catheterized before and after intravenous administration of fenoldopam, 0.05 μg/kg/min for 1 hr and increased to 0.1 μg/kg/min for another hour. Mean arterial pressure progressively decreased (from 83 ± 7 to a minimum of 77 ± 8 mm Hg 100 min after starting the infusion) but returned to baseline level at 120 min. Plasma norepinephrine and renin activity increased (respectively from 567 ± 297 to 919 ± 375 pg/ml, p < 0.05, and from 17 ± 14 to 23 ± 15 ng/ml/hr, p < 0.05). Renal blood flow, urine output or sodium excretion did not change. Sodium output decreased at 1 hr from 6.9 μmol/min to 4.0 μmol/min, p < 0.05. Both hepatic venous pressure gradient and azygos blood flow significantly increased by 21%. We conclude that the acute administration of fenoldopam did not improve renal hemodynamics or function in patients with cirrhosis and ascites. In addition, dopamine DA 1 agonism caused further increases in norepinephrine concentration and plasma renin activity. Portal pressure also increased, probably because of an increase in mesenteric blood flow. These results question the renal benefit and raise concern about the use of dopamine agonists in patients with cirrhosis and ascites. (H EPATOLOGY 1991;13:111–116).